Spots Global Cancer Trial Database for Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Official Title: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Study ID: NCT02013336
Study Description
Brief Summary: This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.
Detailed Description:
Eligibility
Minimum Age: 12 Months
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
UT Southwestern, Dallas, Texas, United States
MD Anderson Children's Cancer Hospital, Houston, Texas, United States
Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Midwest Children's Hospital, Milwaukee, Wisconsin, United States
Contact Details
Name: Paul Harker-Murray, MD
Affiliation: Midwest Children's Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
